Literature DB >> 15476893

Nijmegen breakage syndrome and DNA double strand break repair by NBS1 complex.

Shinya Matsuura1, Junya Kobayashi, Hiroshi Tauchi, Kenshi Komatsu.   

Abstract

The isolation of the NBS1 gene revealed the molecular mechanisms of DSB repair. In response to DNA damage, histone H2AX in the vicinity of DSBs is phosphorylated by ATM. NBS1 then targets the MRE11/RAD50 complex to the sites of DSBs through interaction of the FHA/BRCT domain with gamma-H2AX. NBSI complex binds to damaged-DNA directly, and HR repair is initiated. To collaborate DSB repair, ATM also regulates cell cycle checkpoints at GI, G2, and intra-S phases via phosphorylation of SMC, CHK2 and FANCD2. The phosphorylation of these proteins require NBS1 complex. Thus, NBSI has at least two important roles in genome maintenance, as a DNA repair protein in HR pathway and as a signal modifier in intra-S phase checkpoints. NBSI is also known to be involved in maintenance of telomores, which have DSB-like structures and defects here can cause telomcric fusion. Therefore, NBS1 should be a multi-functional protein for the maintenance of genomic integrity. Further studies on NBS1 will provide insights into the mechanisms of DNA damage response and the network of these factors involved in genomic stability.

Entities:  

Year:  2004        PMID: 15476893

Source DB:  PubMed          Journal:  Adv Biophys        ISSN: 0065-227X


  16 in total

1.  Genetic variation in the NBS1 gene is associated with hepatic cancer risk in a Chinese population.

Authors:  Ming-De Huang; Xiao-Fei Chen; Gang Xu; Qing-Quan Wu; Jian-Huai Zhang; Guo-Feng Chen; Yong Cai; Fu-Zhen Qi
Journal:  DNA Cell Biol       Date:  2011-11-09       Impact factor: 3.311

2.  Carriage of NBN polymorphisms and acute leukemia risk.

Authors:  Yan Wang; Zhongliang Sun; Yuan Xu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Association between the NBS1 Glu185Gln polymorphism and breast cancer risk: a meta-analysis.

Authors:  Fan Yao; Yue Fang; Bo Chen; Feng Jin; Shubao Wang
Journal:  Tumour Biol       Date:  2013-02-05

4.  The NBS1 genetic polymorphisms and the risk of the systemic lupus erythematosus in Taiwanese patients.

Authors:  Ying-Ju Lin; Yu-Ching Lan; Lei Wan; Chung-Ming Huang; Cheng-Wen Lin; Kai-Chung Hsueh; Da-Yuan Chen; Ting-Hsu Lin; Fuu-Jen Tsai
Journal:  J Clin Immunol       Date:  2010-06-23       Impact factor: 8.317

5.  Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.

Authors:  Lori Rink; Artur Slupianek; Tomasz Stoklosa; Margaret Nieborowska-Skorska; Katarzyna Urbanska; Ilona Seferynska; Krzysztof Reiss; Tomasz Skorski
Journal:  Blood       Date:  2007-04-12       Impact factor: 22.113

6.  NBS1 rs1805794G>C polymorphism is associated with decreased risk of acute myeloid leukemia in a Chinese population.

Authors:  Na Li; Yanzhe Xu; Jian Zheng; Lan Jiang; Yonghe You; Hongchun Wu; Wei Li; Depei Wu; Yifeng Zhou
Journal:  Mol Biol Rep       Date:  2013-01-03       Impact factor: 2.316

7.  The Mre11 complex mediates the S-phase checkpoint through an interaction with replication protein A.

Authors:  Erin Olson; Christian J Nievera; Enbo Liu; Alan Yueh-Luen Lee; Longchuan Chen; Xiaohua Wu
Journal:  Mol Cell Biol       Date:  2007-06-25       Impact factor: 4.272

8.  NBS1 Glu185Gln polymorphism and susceptibility to urinary system cancer: a meta-analysis.

Authors:  Ying Zhang; Yu-Shan Huang; Wen-Qian Lin; Shao-Dan Zhang; Qi-Wen Li; Ye-Zhu Hu; Rong-Liang Zheng; Tao Tang; Xi-Zhao Li; Xiao-Hui Zheng
Journal:  Tumour Biol       Date:  2014-07-30

9.  NBS1 Phosphorylation Status Dictates Repair Choice of Dysfunctional Telomeres.

Authors:  Rekha Rai; Chunyi Hu; Cayla Broton; Yong Chen; Ming Lei; Sandy Chang
Journal:  Mol Cell       Date:  2017-02-16       Impact factor: 19.328

10.  Evolutionary genomics of human intellectual disability.

Authors:  Bernard Crespi; Kyle Summers; Steve Dorus
Journal:  Evol Appl       Date:  2009-09-07       Impact factor: 5.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.